An interventional study of Intensive Prevention Strategy in Type 2 Diabetes, Diabetic Cardiomyopathy and Heart Failure, sponsored by University of Texas Southwestern Medical Center. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Prevention
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Primary care providers will be randomized to receive notifications via the electronic health record if any patients with diabetes have high heart failure risk based on a combination of clinical risk scores(WATCH-DM), and biomarkers (NT-proBNP). Providers will be provided recommendation to initiate evidence based therapies (SGLT2 inhibitors, GLP1 agonists, non-steroidal MRA) , obtain expert e-consultation, or refer the patient to a cardiometabolic risk management program.
Exclusion Criteria:
Primary care providers (PCP) randomized to the Risk Assessment and Intensive Prevention Strategy Arm will receive notification if any patients with diabetes under their care have high heart failure risk based on clinical or biomarker scores. Providers will receive recommendations, option for e-consultation, and referral to cardiometabolic risk management program.
Behavioral: Intensive Prevention Strategy
Primary care providers randomized to the Usual care arm will not receive any notifications about patients with diabetes and their HF risk assessment.
Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Incident Heart Failure or All-cause death
Incident Heart Failure (based on electronic health record International Classification of Diseases codes) or all-cause death. This will be assessed via retrospective chart review.
Time frame: 2-year follow-up
Prescription Rates of SGLT2i
Counts of SGLT2 inhibitor prescriptions filled
Time frame: 6-months from electronic health record alert.
Prescription Rate of Finerenone
Counts of Finerenone prescriptions
Time frame: 6-months from electronic health record alert.
Prescription Rate of GLP1
Counts of GLP1 prescription
Time frame: 6-months from electronic health record alert.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center